S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
3 Dividend Growers With Good 2023 Growth Prospects
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Build Your Quality of Life by Investing in Your Lifestyle
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Dark Clouds Are Gathering For Cloud Stocks 
Hormel: Is This The Time To Buy?
NASDAQ:FEMY

Femasys - FEMY Stock Forecast, Price & News

$1.08
-0.05 (-4.42%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.04
$1.14
50-Day Range
$1.05
$1.41
52-Week Range
$0.99
$5.64
Volume
17,445 shs
Average Volume
16,122 shs
Market Capitalization
$12.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Femasys MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
579.0% Upside
$7.33 Price Target
Short Interest
Healthy
0.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Femasys in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.98) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

260th out of 1,047 stocks

Surgical & Medical Instruments Industry

30th out of 104 stocks

About Femasys

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

FEMY Stock News Headlines

Femasys Third Quarter 2022 Earnings: Misses Expectations
Femasys Inc. (FEMY)
Femasys (FEMY) Investor Presnetation - Slideshow
CENN, TMC and QTT among pre market gainers
See More Headlines
Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

FEMY Company Calendar

Last Earnings
11/10/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FEMY
Fax
N/A
Employees
27
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+579.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-7,540,000.00
Net Margins
-886.22%
Pretax Margin
-885.89%

Debt

Sales & Book Value

Annual Sales
$1.18 million
Book Value
$1.52 per share

Miscellaneous

Free Float
9,359,000
Market Cap
$12.75 million
Optionable
Not Optionable
Beta
-0.27

Key Executives

  • Ms. Kathy Lee-Sepsick (Age 55)
    Founder & CEO and Pres
    Comp: $566.72k
  • Mr. Daniel Scott Currie (Age 58)
    SVP of Operations & Sec.
    Comp: $411.46k
  • Mr. Dov Elefant (Age 55)
    Chief Financial Officer
  • Ms. Mary An Merchant J.D.
    Ph.D., VP of Counsel & Intellectual Property
  • Mr. Steven P. Damon (Age 66)
    VP of Bus. Devel.
  • Mr. Todd A. Creech MBA (Age 54)
    Chief Financial Advisor
  • Dr. Jeffrey Marcus M.D.
    M.S., Chief Medical Advisor
  • Dr. Edward G. Evantash M.D. (Age 59)
    Chief Medical Officer
  • Ms. Christine Thomas
    Sr. VP of Regulatory & Clinical Affairs













FEMY Stock - Frequently Asked Questions

Should I buy or sell Femasys stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings
or view top-rated stocks.

What is Femasys' stock price forecast for 2023?

3 Wall Street analysts have issued twelve-month price objectives for Femasys' stock. Their FEMY share price forecasts range from $5.00 to $12.00. On average, they predict the company's stock price to reach $7.33 in the next year. This suggests a possible upside of 579.0% from the stock's current price.
View analysts price targets for FEMY
or view top-rated stocks among Wall Street analysts.

How have FEMY shares performed in 2022?

Femasys' stock was trading at $3.90 at the beginning of the year. Since then, FEMY shares have decreased by 72.3% and is now trading at $1.08.
View the best growth stocks for 2022 here
.

When is Femasys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our FEMY earnings forecast
.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) announced its earnings results on Wednesday, November, 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The business earned $0.27 million during the quarter. Femasys had a negative net margin of 886.22% and a negative trailing twelve-month return on equity of 48.96%.

When did Femasys IPO?

(FEMY) raised $35 million in an IPO on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

What is Femasys' stock symbol?

Femasys trades on the NASDAQ under the ticker symbol "FEMY."

Who are Femasys' major shareholders?

Femasys' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.16%) and Tri Locum Partners LP (0.90%).
View institutional ownership trends
.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Femasys' stock price today?

One share of FEMY stock can currently be purchased for approximately $1.08.

How much money does Femasys make?

Femasys (NASDAQ:FEMY) has a market capitalization of $12.76 million and generates $1.18 million in revenue each year. The company earns $-7,540,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How can I contact Femasys?

The official website for the company is www.femasys.com. The company can be reached via phone at 770-500-3910 or via email at ir@femasys.com.

This page (NASDAQ:FEMY) was last updated on 12/1/2022 by MarketBeat.com Staff